Notice of price stabilization in Bactiguard Holding
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN.
Swedbank AB (publ) (”Swedbank”) has exercised the possibility to, in connection with the initial public offering (“IPO”) of Bactiguard Holding AB (publ) (“Bactiguard” or the”Company”), exercise price stabilization transactions.
The stabilization period commenced on June 19, 2014 and ended on July 18, 2014. All stabilization transactions were carried out in the interval of SEK 28.55 to SEK 37.85. The stabilization period has now ended and no further stabilization transactions will be exercised.
| Date | Price |
| June 19, 2014 | 37.85 |
| June 23, 2014 | 32.28 |
| June 24, 2014 | 33.40 |
| June 25, 2014 | 33.00 |
| June 26, 2014 | 32.80 |
| June 30, 2014 | 33.90 |
| July 2, 2014 | 33.16 |
| July 3, 2014 | 31.87 |
| July 4, 2014 | 30.33 |
| July 15, 2014 | 29.54 |
| July 16, 2014 | 29.50 |
| July 17, 2014 | 28.55 |
The 1,638,336 B-shares in Bactiguard that Swedbank borrowed from Bactiguard B.V. and KK Invest AB, Bactiguard’s main owners, with the purpose to cover the over-allotment in the IPO have been returned. As a result of the return of the B-shares, the main owners will file disclosure notifications.
Swedbank has acted as Lead Manager and Sole Bookrunner and ABG Sundal Collier has acted as Co-Lead Manager in connection with the IPO. Cederquist is legal advisor and Lenner & Partners is financial advisor to the Company.
This is information that Bactiguard Holding AB (publ) is required to publish in compliance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on July 21, 2014 at 07.30 am.
For further information please contact:
Fredrik Järrsten, CFO, mobile: +46 725 500 089
fredrik.jarrsten@bactiguard.com
Bactiguard
Bactiguard is a Swedish medtech company with a mission of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions to the healthcare industry. The company’s patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of coated catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the EU, Middle East, Asia and South America. The company reported sales of approximately SEK 130 million in 2013, has 60 employees, headquarters in Stockholm and production facilities in Markaryd and Malaysia. More information is available at www.bactiguard.se
Tags: